CN104730231A - Sample buffering solution used for fluorescence immunoassay quantitative determination and application of sample buffering solution - Google Patents
Sample buffering solution used for fluorescence immunoassay quantitative determination and application of sample buffering solution Download PDFInfo
- Publication number
- CN104730231A CN104730231A CN201510136850.9A CN201510136850A CN104730231A CN 104730231 A CN104730231 A CN 104730231A CN 201510136850 A CN201510136850 A CN 201510136850A CN 104730231 A CN104730231 A CN 104730231A
- Authority
- CN
- China
- Prior art keywords
- sample
- fluorescence
- whole blood
- fluorescence immunoassay
- sample buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
Abstract
The invention relates to the field of fluorescence immunoassay quantitative determination and particularly relates to a sample buffering solution used for fluorescence immunoassay quantitative determination and application of the sample buffering solution. The sample buffering solution is prepared by centrifuging calf whole blood and taking blood serum, adding a PB buffering solution and mixing, wherein the calf blood serum and the PB buffering solution are mixed in the volume ratio being 1 to 1. The invention further provides a method for the fluorescence immunoassay quantitative determination of a whole blood sample; after the whole blood sample and the sample buffering solution are mixed in the volume ratio being 1 to 2, the mixture is added into a sample cushion of a fluorescence immunoassay quantitative determination test paper strip; and a sample to be detected is detected by using a fluorescence quantitative analyzer. By virtue of the method provided by the invention, whole blood, blood plasma or blood serum is used as the sample to be detected; and the cost is low and a detection result is not interfered.
Description
Technical field
The present invention relates to fluorescence immunoassay quantitative detection field, be specifically related to a kind of sample buffer of quantitatively detecting for fluorescence immunoassay and application thereof.
Background technology
Immunolabelling technique refers to fluorescein, radioactive isotope, enzyme, ferritin, collaurum and chemistry (or biological) luminous agent etc. as tracer, the antigen-antibody reaction that labelled antibody or antigen carry out, and by means of exact instrument such as fluorescent microscope, ray meter, enzyme mark detector, electron microscope and luminescent immunoassay instrument, apply various liquid phase and solid phase immunoassays formats, quantitative and qualitative analysis method for measuring is carried out to the haptens in body fluid, antigen or antibody.Time resolved fluoro-immunoassay (Timed-resolved fluoroimmunoassay, TRFIA) be a kind of sensitive high-end quantitative immunological detection technique, come labelled antigen or antibody using La rear earth ion as label, because La rear earth ion has unique fluorescent characteristic, this technology can obtain high signal to noise ratio (S/N ratio), thus there is very high sensitivity, and also there is label prepare easy, storage time is long, no radioactivity pollute, detect reproducible, operating process is short, standard curve range is wide, by the interference of sample natural fluorescence and the advantage such as range of application is very extensive.Time resolved fluoro-immunoassay exempts from analysis relative to enzyme, radiommunoassay has higher clinical value.This technology is applicable to the clinical detection of various antigen-antibody, is commercially used widely.
Fluorescence immune chromatography is that be based upon enzyme linked immunosorbent assay, latex agglutination test, monoclonal antibody technique and immunofluorescence microballoon labelling technique basis take fluorescent microsphere as label, special antigen-antibody reaction is utilized to carry out iodine, by the new technology of quantitative fluorescence analysis instrument result of determination.This technology has the advantages such as simple, quick, accurate and pollution-free, detects many diagnostic fields fast develop rapidly at clinical medicine detection, hormone test, food safety detection, medicament residue and drugs.Along with the deep development of real-time test (POCT) industry, fluorescence immunoassay reagent due to itself with quick, easy, be easy to carry about with one, be convenient to go deep into the feature such as community and outlying mountain area, become the major domain that current POCT develops, thus those are increasing with the demand of anxious, to endanger the Testing index of large disease association fluorescence immunoassay reagent of falling ill.
But detect sample using whole blood sample as the quantitative chromatography of fluorescence immunoassay and carry out detecting large focus and the difficult problem remaining POCT field.The quantitative chromatography of fluorescence immunoassay is when using plasma/serum as detection sample, and testing result is highly sensitive, and detection method is easy, quick, specificity is high.But during using whole blood sample as detection sample, due to existence erythrocytic in whole blood, once red blood cell is leaked on test strips NC film during detection, then can have an impact to the gathering of fluorescent microsphere on NC film detection line and control line, thus cause vacation sun or the false negative of testing result.Consider separation of serum/blood plasma and some operation stepss, at least need a hours, and in the medical institutions without technical conditions, also cannot carry out.Therefore, the other diagnostic assay of the bed that a kind of whole blood carries out analyzing, namely whole blood immunity chromatography Faxian is most important.The sample buffer detected for whole blood sample also just becomes the key of fluorescence immunoassay quantitative testing test paper bar in clinical practice.The present invention is devoted to seek a kind of fluorescence immunoassay quantitative testing test paper bar and the sample buffer that effectively can detect whole blood sample fast, detects whole blood sample.Thus serve more fast and effectively for hospital clinical and patient provide and treat.
But, mostly only several companies producing fluorescence immunoassay quantitative test paper are using anti-human erythrocyte (RBC) antibody as whole blood test sample buffer on the market at present, this method needs to carry out animal immune experiment, cultured cell also relates to the series of experiments operations such as Isolation and purification RBC antibody, process is loaded down with trivial details, and requires very high to RBC antibody purity.Once purity does not reach requirement, very large on testing result impact.So far, also not about the report adopting calf serum as the sample buffer of whole blood test, therefore, the present invention openly mixes by calf serum the methods and applications carrying out detecting by a certain percentage at first time as sample buffer and whole blood sample.
Summary of the invention
Not enough for prior art, the object of this invention is to provide a kind of fluorescence immunoassay quantitative testing test paper bar, can effectively detect whole blood/plasma/serum sample fast.
For achieving the above object, first the present invention provides a kind of sample buffer quantitatively detected for fluorescence immunoassay, and described sample buffer, by after whole bovine blood centrifuging and taking serum, adds the mixing of PB damping fluid and obtains.
Described whole bovine blood is the newborn ox blood of fresh collection, and the IgM content inside newborn ox blood is maximum, and concentration is the highest, is beneficial to preservation, and wide material sources, cheap, and dangerous little with infection pathogeny, the sample buffer stable in properties be made into.
As preferably, described calf serum mixes with the volume ratio of 1:1 with described PB damping fluid.This ratio is the optimal proportion of calf serum and PB damping fluid, and in the calf serum adopting this ratio to mix, IgM concentration is the erythrocytic optimum concentration of aggegation, and can reduce the loss of calf serum.
As preferably, described centrifugal be low-speed centrifugal, best with centrifugal 5 minutes of 4000r/min, object is that the high molecular weight proteins such as the IgM prevented in blood plasma are centrifuged out, thus affects the use of sample buffer.
Present invention also offers the application of aforementioned sample buffer in whole blood/plasma/serum sample fluorescence immune quantitative detects.
Further, be applied as fluorescence immunoassay described in and quantitatively detect Applications of Cardiac Markers in whole blood sample.
Present invention also offers a kind of method that whole blood sample fluorescence immunoassay quantitatively detects, be specially after whole blood sample is mixed with aforementioned sample buffer, be added in the sample pad of fluorescence immunoassay quantitative testing test paper bar, utilize quantitative fluorescence analysis instrument to detect sample to be tested.
As preferably, described whole blood sample mixes with the volume ratio of 1:2 with described sample buffer.
Further, described fluorescence immunoassay quantitative testing test paper bar is made up of glass fibre membrane, polyester glass fibre, nitrocellulose filter, absorbent filter and PVC board; The thickness of described glass fibre membrane is 0.52mm, and fibre diameter is 0.6-3.0 μm, and it is as sample pad filter whole blood best results.
Further, described polyester glass fibre is as fluorescence labeling pad, and its thickness is 0.25mm, and water absorbing capacity is 49.25mg/cm
2, it has good water wettability and release property, can reduce the interference to testing result.In described fluorescence detection test, nitrocellulose filter is as reaction zone.
Present invention also offers a kind of method that plasma/serum sample fluorescence immune quantitative detects, be specially after plasma/serum sample is mixed with aforementioned sample buffer, be added in the sample pad of fluorescence immunoassay quantitative testing test paper bar, utilize quantitative fluorescence analysis instrument to detect sample to be tested.
As preferably, described plasma/serum sample mixes with the volume ratio of 1:3 with described sample buffer.
Beneficial effect of the present invention is:
The present invention adopts calf serum to prepare sample buffer, not only reduces the cost of product, and has good stability and repeatability; By adding a certain proportion of PB damping fluid in calf serum, the fluorescence detection test sample buffer of preparation, in liquid, compared to other whole blood test methods on current domestic and international market, using calf serum as sample buffer, can realize detecting using whole blood, blood plasma or serum as sample, with low cost, and noiseless to testing result.And can better for fluorescence immunoassay quantitative test, detect fast, result is accurate, easy and simple to handle, and other whole blood test method is mainly with anti-human erythrocyte antibody treatment whole blood sample, cost of manufacture is high, and process is loaded down with trivial details, and testing process easily causes nonspecific reaction, thus affect testing result.
Accompanying drawing explanation
Fig. 1 is fluorescence immunoassay quantitative testing test paper schematic diagram;
Fig. 2 is red cell agglutination schematic diagram;
Fig. 3 is that BCA method surveys protein concentration typical curve;
Fig. 4 is fluorescence immunoassay quantitative testing test paper bar whole blood test effect schematic diagram (1 ~ 6 be respectively whole blood and sample buffer mixes by 1:5,1:4,1:3,1:2,1:1,2:1 ratio);
Fig. 5 is cardiac muscle troponin I concentration standard curve.
Embodiment
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
The preparation of the sample buffer that embodiment 1 quantitatively detects for fluorescence immunoassay
71.6g Na is taken respectively with electronic balance
2hPO
412H
2o, 31.2gNaH
2pO
42H
2o, is dissolved in 1000mL distilled water respectively, is mixed with 0.2M mother liquor separately.Get 19mL 0.2M NaH
2pO
4mother liquor, 81mL 0.2M Na
2hPO
4mother liquor, mixing is placed in volumetric flask, and adding distil water is settled to 1000mL, is mixed with the PB damping fluid of 0.02M pH7.4.Get the calf serum (centrifugal 5 minutes of fresh calf whole blood 4000r/min) that certain quantity of fresh gathers, mix with aforementioned PB damping fluid with the ratio of 1:1, shaken well.Packing is propped up by 180 μ L/, stand-by.
The optimization of calf serum and PB damping fluid blending ratio in embodiment 2 sample buffer
By the calf serum stoste of fresh collection, and with PB damping fluid through 2:1,1:1, after 1:3 serial dilution, carry out immune precipitation with quantitative solution of red blood cells, optimize the suitableeest mixing ratio of calf serum and PB damping fluid, testing result is as shown in table 1.
Table 1: calf serum and PB damping fluid blend proportion optimization result
As can be seen from Table 1, IgM too high levels in calf serum stoste, cause occurring front band effect in immunoreaction process too early, red cell agglutination is incomplete.After calf serum dilution ratio is more than 1:2, there is hook effect in the concentration also corresponding reduction of IgM, and red blood cell is all aggegations not.When calf serum and PB damping fluid blending ratio are 2:1 or 1:1, the concentration of IgM is comparatively applicable, and react comparatively complete with red blood cell, both aggegation effects are close.Consider the problem of production cost, finally get calf serum and mix in 1:1 ratio with PB damping fluid.
Embodiment 3
1, the preparation of calf serum
Put into about 30ml physiological saline in advance in blood collecting bottle, fully drench blood collecting bottle, heparin tube, so that being separated of blood and bottle wall.Get blood from calf arteria carotis, allow blood naturally slowly flow in blood collecting bottle, get blood complete by blood collecting bottle room temperature (being advisable for about 25 DEG C) tiltedly placement 4 hours, after blood fully cools, then put people's 4 DEG C of refrigerator overnight, allow serum fully separate out.Next day, careful Aspirate supernatant, moved into 10ml tool plug centrifuge tube, centrifugal 5 minutes with 4000 revs/min, collects serum in superclean bench.Yield after calf serum is centrifugal is as shown in table 2.
Yield after table 2 calf serum is centrifugal
2, protein concentration detects
Calf serum contains the protein of high concentration, comprises plasma proteins, IgG, IgM etc.Wherein, the composition played a major role is IgM.IgM is high molecular weight protein, with the specific antigen generation antigen-antibody reaction on erythrocyte membrane, thus can reach coupling red blood cell, and promote the effect of red cell agglutination, Fig. 2 is shown in coupling agglutinating reaction.In calf serum, protein concentration is higher, and IgM concentration is then higher, and the effect of generation is better.Therefore, BCA method is adopted to measure protein concentration in calf serum.Convert by Fig. 3 protein concentration typical curve, Bovine serum albumin concentration determination result is 48.5mg/ml.Therefore select calf serum as the component of sample buffer.
3, the preparation of fluorescence immunoassay quantitative testing test paper bar
Get fluorescent microsphere solution, add anti-Applications of Cardiac Markers antibody, after stirring at room temperature 30min, add the bovine serum albumin solution termination that concentration is 1%, in 12000rpm, after 4 DEG C of refrigerated centrifuges, again centrifugal after containing 0.5% bovine serum albumin(BSA) cleaning with 10mM phosphate buffer, with redissolution liquid, (10mM phosphate buffer contains 0.5% bovine serum albumin(BSA), 2% sucrose, 0.1% Sodium azide) fluorescently-labeled anti-Applications of Cardiac Markers antibody is suspended, 4 DEG C save backup, this suspending liquid is sprayed on glass fibre membrane with the speed of 1.8 μ L/cm by the three-dimensional specking platform using Biodot to draw film instrument, dry 8 hours in 35 ~ 38 DEG C.With the PBS damping fluid of pH7.2 by anti-Applications of Cardiac Markers antibody with how anti-sheep anti mouse is is diluted to 0.5mg/mL and 0.7mg/mL respectively, both with the even spray printing in the interval of 1.5cm on NC film (as Fig. 1), dry 8 hours in 35 ~ 38 DEG C by the three-dimensional specking platform using Biodot to draw film instrument.Get above-mentioned glass fibre membrane (sample pad), nitrocellulose filter (NC film), absorbent filter (absorption pad) be pasted in PVC board successively.After assembling, with cutting cutter specification slitting on demand.The sample buffer prepared with embodiment 1 with the use of.
Embodiment 4
1, whole blood test is filtered
Get same batch of fluorescence immunoassay quantitative testing test paper bar, people's venous whole and sample buffer are pressed 1:5 respectively, after the ratio mixing of 1:4,1:3,1:2,1:1,2:1, get 100 μ L mixed liquor application of samples, test.Fluorescence immunoassay quantitative testing test paper bar filter whole blood effect as shown in Figure 4.As seen from Figure 4, when whole blood sample and sample buffer press the dilution proportion of 1:2, in the IgM in sample buffer and whole blood, the antigen concentration ratio of erythrocyte surface is the most suitable, reaches optimum ratio, antigen-antibody fully combines, and the effect of filter whole blood reaches best.When adopting the mixing of other ratios, before causing because antigen-antibody ratio is improper occurring band effect or after be with effect, red blood cell cannot aggegation completely, thus leaks out sample pad.
2, Applications of Cardiac Markers cardiac muscle troponin I test
The drafting of 2.1 typical curves
The standard solution of cardiac muscle troponin I is mixed with the solution of 50ng/mL, 25ng/mL, 10ng/mL, 2.5ng/mL, 0.5ng/mL, 0.1ng/mL variable concentrations, by the test strips of same batch, each sample concentration tests 5, by fluorescent quantitative detector sentence read result, as shown in table 2.According to statistical method, with the signal intensity of detection line for ordinate, the solution concentration of cardiac muscle troponin I is horizontal ordinate, sets up equation and fits to typical curve, as shown in Figure 5.From Fig. 5 and table 3, when the solution concentration of cardiac muscle troponin I is 0.1ng/mL, detection line still has Signal aspects, along with the increase gradually of the solution concentration of cardiac muscle troponin I, the signal intensity of detection line also strengthens thereupon, both proportional example displays, can be obtained by experiment, the detection sensitivity of test strips cardiac muscle troponin I of the present invention reaches 0.1ng/mL, and CV is within 10%, reproducible.
Table 3 cardiac muscle troponin I typical curve
The detection of 2.2 samples:
(1) keep flat test strips, get whole blood sample, after putting upside down mixing, be divided into 2 parts, get a with the centrifugal 10min of 4000g, get blood plasma, after mixing with sample buffer in the ratio of 1:3, get 100 μ L and be added in sample pad.Get after another part of whole blood sample mix with sample buffer in the ratio of 1:2, get 100 μ L and be added in sample pad, room temperature reaction 15 minutes; (2) open detection equipment, and card inserting mouth detector bar and calibration card being inserted checkout equipment, run instrument, instrument calculates the concentration of the cardiac muscle troponin I solution in sample to be tested automatically by corresponding analysis software.Detect with Beckman Ku Erte DXI800 Full-automatic chemiluminescence immunoassay analysis meter and contrast, according to statistical method, the mean value of calculating myocardium Troponin I concentration, as shown in table 4.
Table 4 whole blood sample accuracy detects
As can be seen from Table 3, test strips of the present invention and sample buffer to the whole blood of same sample and blood plasma testing result deviation little, sample buffer is to the noiseless reaction of testing result, and both testing results are also more consistent with Beckman Ku Erte DXI800 Full-automatic chemiluminescence immunoassay analysis meter testing result.Show that test strips of the present invention and sample buffer possess good accuracy.
Although above with general explanation, embodiment and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (10)
1. for the sample buffer that fluorescence immunoassay quantitatively detects, it is characterized in that, described sample buffer, by after whole bovine blood centrifuging and taking serum, adds the mixing of PB damping fluid and obtains.
2. sample buffer according to claim 1, is characterized in that, described calf serum mixes with the volume ratio of 1:1 with described PB damping fluid.
3. sample buffer according to claim 1 and 2, is characterized in that, the centrifugal centrifugal condition of described whole bovine blood is 4000r/min, 5 minutes.
4. the application of the sample buffer described in any one of claim 1-3 in whole blood/plasma/serum sample fluorescence immune quantitative detects.
5. application according to claim 4, is characterized in that, described in be applied as fluorescence immunoassay and quantitatively detect Applications of Cardiac Markers in whole blood sample.
6. the method that quantitatively detects of a whole blood sample fluorescence immunoassay, it is characterized in that, after whole blood sample is mixed with the sample buffer described in any one of claim 1-3, be added in the sample pad of fluorescence immunoassay quantitative testing test paper bar, utilize quantitative fluorescence analysis instrument to detect sample to be tested.
7. method according to claim 6, is characterized in that, described whole blood sample mixes with the volume ratio of 1:2 with described sample buffer.
8. the method according to claim 6 or 7, is characterized in that, described fluorescence immunoassay quantitative testing test paper bar is made up of glass fibre membrane, polyester glass fibre, nitrocellulose filter, absorbent filter and PVC board; The thickness of described glass fibre membrane is 0.52mm, and fibre diameter is 0.6-3.0 μm.
9. method according to claim 8, is characterized in that, described polyester glass fibre is as fluorescence labeling pad, and its thickness is 0.25mm, and water absorbing capacity is 49.25mg/cm
2.
10. the method for a plasma/serum sample fluorescence immune quantitative detection, it is characterized in that, after plasma/serum sample is mixed with the sample buffer described in any one of claim 1-3, be added in the sample pad of fluorescence immunoassay quantitative testing test paper bar, utilize quantitative fluorescence analysis instrument to detect sample to be tested; Described plasma/serum sample mixes with the volume ratio of 1:3 with described sample buffer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510136850.9A CN104730231B (en) | 2015-03-26 | 2015-03-26 | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510136850.9A CN104730231B (en) | 2015-03-26 | 2015-03-26 | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104730231A true CN104730231A (en) | 2015-06-24 |
| CN104730231B CN104730231B (en) | 2016-06-08 |
Family
ID=53454329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510136850.9A Active CN104730231B (en) | 2015-03-26 | 2015-03-26 | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104730231B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106198954A (en) * | 2016-07-21 | 2016-12-07 | 王雅 | A kind of sample buffer for fluorescence immunoassay detection by quantitative |
| CN107144693A (en) * | 2017-05-02 | 2017-09-08 | 暨南大学 | Detect CD4 in blood+Lateral chromatography kit of T cell quantity and preparation method thereof |
| CN113049809A (en) * | 2019-12-28 | 2021-06-29 | 深圳市帝迈生物技术有限公司 | Detection kit for detecting eight cardiac markers and detection method for eight cardiac markers |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092173A (en) * | 1993-03-11 | 1994-09-14 | 中国人民解放军南京军区后勤部军事医学研究所 | The compound method of ABO blood group system monoclonal antibody somatotype reagent and application liquid thereof |
| CN1434297A (en) * | 2003-01-24 | 2003-08-06 | 武汉大学 | Enzyme immunological method for quickly detecting rubella virus antibody |
| CN1664584A (en) * | 2005-01-31 | 2005-09-07 | 上海市血液中心 | An antigen-antibody dilution liquid and quality controlled produce formed thereby |
| CN1967249A (en) * | 2005-11-15 | 2007-05-23 | 华中科技大学同济医学院附属协和医院 | Four conjunction diagnostic kit of antimyocardial antibody |
| CN101368973A (en) * | 2008-04-29 | 2009-02-18 | 北京科美东雅生物技术有限公司 | Chemical luminescence immune assay determination reagent kit for detecting human growth hormone |
| EP2174954A1 (en) * | 2000-10-18 | 2010-04-14 | The Brigham and Women's Hospital, Inc. | Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| CN102087293A (en) * | 2010-12-31 | 2011-06-08 | 广州万孚生物技术有限公司 | Immunochromatographic test strip for quantitatively detecting troponin I in whole course and preparation method thereof |
| CN102680697A (en) * | 2011-03-10 | 2012-09-19 | 北京吉奥众艺科技有限公司 | Reagent kit for detecting troponin I and preparation and use method thereof |
| CN102798718A (en) * | 2012-08-31 | 2012-11-28 | 福建省洪诚生物药业有限公司 | Previous S1 antigen detection kit for hepatitis B virus and preparation method of previous S1 antigen detection kit |
| CN103175970A (en) * | 2013-02-05 | 2013-06-26 | 福建省洪诚生物药业有限公司 | CA19-9 quantitative detection kit and preparation method of kit |
-
2015
- 2015-03-26 CN CN201510136850.9A patent/CN104730231B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092173A (en) * | 1993-03-11 | 1994-09-14 | 中国人民解放军南京军区后勤部军事医学研究所 | The compound method of ABO blood group system monoclonal antibody somatotype reagent and application liquid thereof |
| EP2174954A1 (en) * | 2000-10-18 | 2010-04-14 | The Brigham and Women's Hospital, Inc. | Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| CN1434297A (en) * | 2003-01-24 | 2003-08-06 | 武汉大学 | Enzyme immunological method for quickly detecting rubella virus antibody |
| CN1664584A (en) * | 2005-01-31 | 2005-09-07 | 上海市血液中心 | An antigen-antibody dilution liquid and quality controlled produce formed thereby |
| CN1967249A (en) * | 2005-11-15 | 2007-05-23 | 华中科技大学同济医学院附属协和医院 | Four conjunction diagnostic kit of antimyocardial antibody |
| CN101368973A (en) * | 2008-04-29 | 2009-02-18 | 北京科美东雅生物技术有限公司 | Chemical luminescence immune assay determination reagent kit for detecting human growth hormone |
| CN102087293A (en) * | 2010-12-31 | 2011-06-08 | 广州万孚生物技术有限公司 | Immunochromatographic test strip for quantitatively detecting troponin I in whole course and preparation method thereof |
| CN102680697A (en) * | 2011-03-10 | 2012-09-19 | 北京吉奥众艺科技有限公司 | Reagent kit for detecting troponin I and preparation and use method thereof |
| CN102798718A (en) * | 2012-08-31 | 2012-11-28 | 福建省洪诚生物药业有限公司 | Previous S1 antigen detection kit for hepatitis B virus and preparation method of previous S1 antigen detection kit |
| CN103175970A (en) * | 2013-02-05 | 2013-06-26 | 福建省洪诚生物药业有限公司 | CA19-9 quantitative detection kit and preparation method of kit |
Non-Patent Citations (1)
| Title |
|---|
| 何莉芳和刘静: "一种简易的小牛血清制备方法", 《生物学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106198954A (en) * | 2016-07-21 | 2016-12-07 | 王雅 | A kind of sample buffer for fluorescence immunoassay detection by quantitative |
| CN107144693A (en) * | 2017-05-02 | 2017-09-08 | 暨南大学 | Detect CD4 in blood+Lateral chromatography kit of T cell quantity and preparation method thereof |
| CN107144693B (en) * | 2017-05-02 | 2019-05-14 | 暨南大学 | Detect the lateral chromatography kit and preparation method thereof of CD4+T cell quantity in blood |
| CN113049809A (en) * | 2019-12-28 | 2021-06-29 | 深圳市帝迈生物技术有限公司 | Detection kit for detecting eight cardiac markers and detection method for eight cardiac markers |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104730231B (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4276259A (en) | Apparatus for performing a radioimmunological method of determining antigens or antibodies | |
| US4292296A (en) | Diagnostic method | |
| CN102636647B (en) | Ketamine-collaurum test paper for detection of saliva | |
| CN104749375A (en) | Method for detecting content of C peptide in human serum, kit used by method and preparation method thereof | |
| CN107389946A (en) | Sugar antigen CA19 9 determines kit and its detection method | |
| CN105403693A (en) | Preparation method of magnetic particle chemiluminescence reagent | |
| CN102901812A (en) | Magnetic particle chemiluminescence immunoassay kit and assay method for human thyroglobulin antibodies (TGAb) | |
| CN203732542U (en) | Test paper card and diagnostic kit for detecting rheumatoid arthritis | |
| CN110007074A (en) | For detecting kit, the preparation method and the usage of c reactive protein | |
| CN109444421A (en) | A kind of preparation method of NSE test strip, test strips, detection card and NSE detection kit | |
| CN104730231B (en) | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof | |
| Exner et al. | An evaluation of currently available methods for plasma fibrinogen | |
| CN102368054B (en) | Chemiluminescence ELISA kit for detecting concentration of drug tacrolimus in human whole blood and Chemiluminescence bottom indicator | |
| CN103969447A (en) | Vascular endothelial growth factor quantitative determination kit and light-emitting substrate solution thereof | |
| CN103063841B (en) | Epidemic hemorrhagic fever (EHF) virus immunoglobulin M (I g M) antibody enzyme-linked immunoassay detection kit and preparation and use method thereof | |
| CN101592660A (en) | Brucellosis indirect enzyme-linked immunosorbent assay milk humoral antibody detection kit | |
| CN102890083A (en) | Chemiluminescence substrate solution, kit containing same, and detection method applying chemiluminescence substrate solution or kit | |
| CN103048477A (en) | Nanometer magnetic particle chemiluminescence detection kit for triiodothyronine as well as preparation method and detecting method of same | |
| Perrault | Naturally-occurring anti-M and anti-N with special case: IgG anti-N in a NN donor | |
| CN101545910A (en) | Ferritin chemoluminescence immunoassay quantitative measuring kit and preparation method thereof | |
| CN114686592B (en) | Kit for multi-type target combined detection, preparation method and use method | |
| AU594922B2 (en) | Method for determining lipid bound sialic acid in whole blood | |
| US4431743A (en) | Method for determining steroids in human body liquids | |
| CN105403706A (en) | Heat shock protein 90 (HSP90) chemiluminescence detection kit | |
| Merry et al. | The quantification of C3 fragments on erythrocytes: estimation of C3 fragments on normal cells, acquired haemolytic anaemia cases and correlation with agglutination of sensitized cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 102200, Beijing Changping District science and Technology Park, super Road, No. 7, building 37 Patentee after: Beijing Lepu Diagnostic Technology Co., Ltd Address before: 102200, Beijing Changping District science and Technology Park, super Road, No. 7, building 37 Patentee before: BEIJING LEPU MEDICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |